Myositis autoantibodies

Current Opinion in Rheumatology

Volumn 24, Issue 6, 2012, Pages 602-608

  Casciola Rosen, Livia ^a   Mammen, Andrew L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autoantibodies; autoantigens; dermatomyositis; myositis; necrotizing myopathy

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; NUCLEAR MATRIX PROTEIN 22; TRANSCRIPTIONAL INTERMEDIARY FACTOR 1 GAMMA; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; DISEASE ASSOCIATION; DISEASE MARKER; HUMAN; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5; MYOPATHY; MYOSITIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

ADENOSINE TRIPHOSPHATASES; AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; DNA-BINDING PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MI-2 NUCLEOSOME REMODELING AND DEACETYLASE COMPLEX; NECROSIS; SIGNAL RECOGNITION PARTICLE; TRANSCRIPTION FACTORS;

EID: 84867018449     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328358bd85     Document Type: Review

References (49)

1. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann NY Acad Sci 2010; 1184:134-153.
2. Wang HB, Zhang Y. Mi2, an auto-antigen for dermatomyositis, is an ATPdependent nucleosome remodeling factor. Nucleic Acids Res 2001; 29:2517-2521. (Pubitemid 32600307)
3. Zhang Y, LeRoyG, Seelig HP, et al. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 1998; 95:279-289. (Pubitemid 28473788)
4. Kashiwagi M, Morgan BA, Georgopoulos K. The chromatin remodeler Mi-2beta is required for establishment of the basal epidermis and normal differentiation of its progeny. Development 2007; 134:1571-1582. (Pubitemid 46746309)
5. Casciola-Rosen L, Nagaraju K, Plotz P, et al. Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med 2005; 201:591-601. (Pubitemid 40289549)
6. Mammen AL, Casciola-Rosen LA, Hall JC, et al. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009; 60:3784-3793.
7. Burd CJ, Kinyamu HK, Miller FW, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem 2008; 283:34976-34982.
8. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52:1571-1576. (Pubitemid 40663949)
9. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60:2193-2200.
10. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49:433-440.
11. Fiorentino D, Chung L, Zwerner J, et al. The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study. J Am Acad Dermatol 2011; 65:25-34.
12. Chaisson NF, Paik J, Orbai AM, et al. A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature. Medicine (Baltimore) 2012; 91:220-228.
13. Barral PM, Sarkar D, Su ZZ, et al. Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity. Pharmacol Ther 2009; 124:219-234.
14. Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57:664-678. (Pubitemid 40628855)
15. Danoff SK, Casciola-Rosen L. The lung as a possible target for the immune reaction in myositis. Arthritis Res Ther 2011; 13:230.
16. Targoff IN, Mamyrova G, Trieu EP, et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54:3682-3689. (Pubitemid 44737181)
17. Kaji K, Fujimoto M, Hasegawa M, et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46:25-28. (Pubitemid 44932779)
18. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A, et al. Usefulness of antip155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012; 64:523-532.
19. Targoff IN, Trieu E, Levy-Neto M, et al. Autoantibodies to transcriptional intermediary factor 1-gamma (TIF1-g) in dermatomyositis [abstract]. Arthritis Rheum 2006; 55:S518.
20. Fujimoto M, Hamaguchi Y, Kaji K, et al. Myositis-specific anti155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012; 64:513-522.
21. Dupont S, Mamidi A, Cordenonsi M, et al. FAM/USP9x, a deubiquitinating enzyme essential for TGFbeta signaling, controls Smad4 monoubiquitination. Cell 2009; 136:123-135.
22. Allton K, Jain AK, Herz HM, et al. Trim24 targets endogenous p53 for degradation. Proc Natl Acad Sci USA 2009; 106:11612-11616.
23. Tsai WW, Wang Z, Yiu TT, et al. TRIM24 links a noncanonical histone signature to breast cancer. Nature 2010; 468:927-932.
24. Wang C, Ivanov A, Chen L, et al. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation. EMBO J 2005; 24:3279-3290. (Pubitemid 41348702)
25. Kong HJ, Anderson DE, Lee CH, et al. Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol 2007; 179:26-30. (Pubitemid 46986512)
26. Oddis CV, Fertig N, Goel A, et al. Clinical and serological characterisation of the anti-MJ antibody in childhood myositis. Arthritis Rheum 1997; 40:S139.
27. Targoff IN, Trieu EP, Levy-Neto M, et al. Sera with autoantibodies to the MJ antigen react with NXP2. Arthritis Rheum 2007; 56:S787.
28. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60:1807-1814.
29. Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol 2009; 36:2547-2551.
30. Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/ dermatomyositis. Arthritis Res Ther 2012; 14:R97.
31. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71:710-713.
32. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA 1986; 83:9507-9511. (Pubitemid 17223389)
33. Satoh T, Okano T, Matsui T, et al. Novel autoantibodies against 7SL RNA in patients with polymyositis/dermatomyositis. J Rheumatol 2005; 32:1727-1733. (Pubitemid 41324811)
34. Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum 1990; 33:1361-1370. (Pubitemid 20365567)
35. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73:420-428.
36. Kao AH, Lacomis D, Lucas M, et al. Antisignal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50:209-215. (Pubitemid 38084306)
37. Hengstman GJ, ter Laak HJ, Vree Egberts WT, et al. Antisignal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 2006; 65:1635-1638. (Pubitemid 44799678)
38. Valiyil R, Casciola-Rosen L, Hong G, et al. Rituximab therapy for myopathy associated with antisignal recognition particle antibodies: a case series. Arthritis Care Res (Hoboken) 2010; 62:1328-1334.
39. Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360-374.
40. Suzuki S, Hayashi YK, Kuwana M, et al. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol 2012; 69:728-732.
41. Romisch K, Miller FW, Dobberstein B, High S. Human autoantibodies against the 54 kDa protein of the signal recognition particle block function at multiple stages. Arthritis Res Ther 2006; 8:R39.
42. Benveniste O, Drouot L, Jouen F, et al. Correlation of antisignal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum 2011; 63:1961-1971.
43. Christopher-Stine L, Casciola-Rosen LA, Hong G, et al. A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immunemediated necrotizing myopathy. Arthritis Rheum 2010; 62:2757-2766.
44. Needham M, Fabian V, Knezevic W, et al. Progressive myopathy with upregulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007; 17:194-200. (Pubitemid 46274372)
45. Grable-Esposito P, Katzberg HD, Greenberg SA, et al. Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 2010; 41:185-190.
46. Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statinassociated autoimmune myopathy. Arthritis Rheum 2011; 63:713-721.
47. Mammen AL, Pak K, Williams EK, et al. Rarity of anti3-hydroxy-3- methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res (Hoboken) 2012; 64:269-272.
48. Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1-11:01 in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012; 64:1233-1237.
49. Werner J, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductase-associated autoimmune myopathy. Arthritis and Rheumatism 2012 (in press).